3-(氯磺酰基)苯甲酸甲酯 | 63555-50-0

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(氯磺酰基)苯甲酸甲酯
• 中文别名: 间氯磺酰基苯甲酸甲酯；3-磺酰氯基苯甲酸甲酯；3-甲氧基羰基苯磺酰氯；3-氯磺酰基苯甲酸甲酯
• 英文名称: methyl 3-chlorosulfonylbenzoate
• 英文别名: 3-(chlorosulfonyl)benzoic acid methyl ester；methyl 3-(chlorosulphonyl)benzoate；3-(Methoxycarbonyl)benzenesulfonyl chloride；Methyl 3-(chlorosulfonyl)benzoate
• CAS: 63555-50-0
• 化学式: C₈H₇ClO₄S
• mdl: MFCD06408800
• 分子量: 234.66
• InChiKey: SQIBNKUEUWGZBH-UHFFFAOYSA-N

物化性质

• 沸点：
  345.6±25.0 °C(Predicted)
• 密度：
  1.431

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2916399090
• WGK Germany：
  3
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P280,P303+P361+P353,P301+P330+P331,P304+P340+P310,P305+P351+P338+P310
• 危险品运输编号：
  3261
• 危险性描述：
  H314
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-(chlorosulfonyl)benzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-(chlorosulfonyl)benzoate
CAS number: 63555-50-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7ClO4S
Molecular weight: 234.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

性状：3-甲氧基羰基苯磺酰氯外观为无色液体。

用途：该化合物可用作中间体，在科学研究和研发中发挥重要作用。

应用：作为有机氯衍生物，3-甲氧基羰基苯磺酰氯广泛应用于有机合成。

反应信息

• 作为反应物：
  描述：

  3-(氯磺酰基)苯甲酸甲酯 在 lithium aluminium tetrahydride 、 四丁基硫酸氢铵 、 potassium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 3-(1H-indol-1-ylsulfonyl)benzaldehyde
  参考文献：
  名称：

  Azaindolylsulfonamides, with a More Selective Inhibitory Effect on Histone Deacetylase 6 Activity, Exhibit Antitumor Activity in Colorectal Cancer HCT116 Cells

  摘要：

  A series of indolylsulfonylcinnamic hydroxamates has been synthesized. Compound 12, (E)-3-(3-((1H-pyrrolo[2,3-b]pyridin-1-yl)sulfonyl)phenyl)-N-hydroxyacrylamide, which has a 7-azaindole core cap, was shown to have antiproliferative activity against KB, H460, PC3, HSC-3, HONE-1, A549, MCF-7, TSGH, MKN45, HT29, and HCT116 human cancer cell lines. Pharmacological studies indicated that 12 functions as a potent HDAC inhibitor with an IC50 value of 0.1 mu M. It is highly selective for histone deacetylase 6 (HDAC6) and is 60-fold more active than against HDAC1 and 223-fold more active than against HDAC2. It has a good pharmacokinetic profile with oral bioavailability of 33%. In in vivo efficacy evaluations in colorectal HCT116 xenografts, compound 12 suppresses tumor growth more effectively than SAHA (1, N-hydroxy-N'-phenyloctanediamide) and is therefore seen as a suitable candidate for further investigation.

  DOI：

  10.1021/jm401899x
• 作为产物：
  描述：

  3-氯磺酰苯甲酰氯 在 吡啶 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 3-(氯磺酰基)苯甲酸甲酯
  参考文献：
  名称：

  PROTON PUMP INHIBITORS

  摘要：

  公开号：

  EP1803709B1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] CONTRAST AGENTS<br/>[FR] AGENTS DE CONTRASTE
  申请人：BRACCO IMAGING SPA

  公开号：WO2017178301A1

  公开（公告）日：2017-10-19

  The present invention relates to new class of functionalized polyazamacrocycles including at least one phosphonic or phosphinic group linked to a nitrogen atom of the macrocyclic cage, and capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.

  本发明涉及一类新型的功能化多氮杂环，至少含有一个与环状笼的氮原子相连的磷onic或磷inic基团，并且能够螯合顺磁性金属离子，及其与金属离子的螯合复合物，以及它们作为对比剂的使用，特别适用于磁共振成像（MRI）分析。
• Correlation of carbon-13 substituent-induced chemical shifts:Meta- andpara-substituted methyl benzoates
  作者：Miloš Buděšńský、Otto Exner

  DOI：10.1002/mrc.1260270612

  日期：1989.6

  Carbon‐13 NMR spectra are reported for 69 substituted methyl benzoates in deuteriochloroform or in its mixture with dimethyl sulphoxide‐d6. The substituent‐induced chemical shifts (SCS) of the CO carbon correlate poorly with dual substituent parameters (DSP) in all possible modifications, and for meta derivatives in particular this correlation is both overpara meterized and imprecise. A much better

  69 取代的苯甲酸甲酯在氘代氯仿中或其与二甲基亚砜-d6 的混合物中的碳 13 NMR 谱报告。在所有可能的修饰中，CO 碳的取代基诱导化学位移 (SCS) 与双取代基参数 (DSP) 的相关性很差，特别是对于间位衍生物，这种相关性既过度参数化又不精确。先前通过主成分分析 (PCA) 从更大的集合中导出的参数（指定为 Bm、Bp 和 Cp）获得了更好的相关性。CH3 碳的 SCS 与原始的简单哈米特方程非常相关，不需要 DSP 处理。在如此大的集合中，取代基的聚类并不重要。
• Manganese-Catalyzed <i>ortho</i>-C-H Amidation of Weakly Coordinating Aromatic Ketones
  作者：Xianqiang Kong、Bo Xu

  DOI：10.1021/acs.orglett.8b01770

  日期：2018.8.3

  An efficient manganese-catalyzed ortho-C-H amidation of weakly coordinating aromatic ketones using the readily available sulfonyl azide as the amination reagent is developed. The key step is the ketone directed aromatic metalation using the in situ generated reactive Mn intermediate, MnMe(CO)5. This method offers excellent chemical yields, high regioselectivities, and good functional group tolerance

  开发了使用易得的磺酰叠氮化物作为胺化试剂的弱配位芳族酮的有效锰催化邻位-CH酰胺化反应。关键步骤是使用原位生成的反应性Mn中间体MnMe（CO）5进行的酮基定向芳族金属化。该方法具有出色的化学收率，高区域选择性和良好的官能团耐受性。